Want to join the conversation?
$ENDP 2Q15 Call: We had a solid second quarter & we are maintaining our underlying guidance for full year 2015 revenues, and adjusted diluted EPS from continuing operations. The relative strength of revenues from our US generic pharmaceuticals business in the second quarter, was again a highlight of the value of our increasingly diversified busines
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.